Limits...
Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction.

Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A, Martín-Moreiras J, Pericacho M, Sánchez PL, Ramirez V, Sánchez-Ledesma M, Martín-Herrero F, Jiménez-Candil J, Maree AO, Sánchez-Rodríguez A, Martín-Luengo C, López-Novoa JM - J. Cell. Mol. Med. (2008)

Bottom Line: Endoglin levels in AMI patients on admission were significantly lower than in healthy controls (4.25 +/- 0.99 ng/ml versus 4.59 +/- 0.87 ng/ml; P= 0.013), and decreased further in the first 48 hours (3.65 +/- 0.76 ng/ml, P < 0.001).Upon follow-up (median 319 days), patients who died had a significantly greater decrease in serum endoglin level over the first 48 hrs than those who survived (1.03 +/- 0.91 versus 0.54 +/- 0.55 ng/ml; P= 0.025).In conclusion, early changes in serum endoglin may predict mortality after AMI.

View Article: PubMed Central - PubMed

Affiliation: Cardiology Division, University Hospital of Salamanca, Salamanca, Spain.

ABSTRACT
Endoglin is a proliferation-associated and hypoxia-inducible protein expressed in endothelial cells. The levels of soluble circulating endoglin and their prognostic significance in patients with acute myocardial infarction (AMI) are not known. In this observational prospective study serum endoglin levels were measured by ELISA in 183 AMI patients upon admission to hospital and 48 hrs later and in 72 healthy controls. Endoglin levels in AMI patients on admission were significantly lower than in healthy controls (4.25 +/- 0.99 ng/ml versus 4.59 +/- 0.87 ng/ml; P= 0.013), and decreased further in the first 48 hours (3.65 +/- 0.76 ng/ml, P < 0.001). Upon follow-up (median 319 days), patients who died had a significantly greater decrease in serum endoglin level over the first 48 hrs than those who survived (1.03 +/- 0.91 versus 0.54 +/- 0.55 ng/ml; P= 0.025). Endoglin decrease was an independent predictor of short-term (30 days) (hazard ratio 2.33;95% CI = 1.27-4.23; P= 0.006) cardiovascular mortality, and also predicts overall cardiovascular mortality during the follow-up (median 319 days) in AMI patients (hazard ratio 2.13;95% CI = 1.20-3.78; P= 0.01). In conclusion, early changes in serum endoglin may predict mortality after AMI.

Show MeSH

Related in: MedlinePlus

Overall survival in AMI patients stratified by early decrease in endoglin. Kaplan–Meier plot representing cumulative overall survival in patients with endoglin decrease (calculated as serum endoglin levels on admission minus serum endoglin levels 48 hrs later) above or below 0.588 ng/ml (value with the best sensitivity and specificity in the ROC analysis). (Log-rank test P= 0.009)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4401139&req=5

fig02: Overall survival in AMI patients stratified by early decrease in endoglin. Kaplan–Meier plot representing cumulative overall survival in patients with endoglin decrease (calculated as serum endoglin levels on admission minus serum endoglin levels 48 hrs later) above or below 0.588 ng/ml (value with the best sensitivity and specificity in the ROC analysis). (Log-rank test P= 0.009)

Mentions: The ROCAUC relating decrease in serum endoglin over the first 48 hrs to overall mortality was 0.65 (95% CI 0.55–0.81; P= 0.007). The highest likelihood ratio corresponded to an endoglin decrease of 0.588 ng/ml (positive likelihood ratio 1.73, negative likelihood ratio 0.49). This value had a sensitivity of 0.72, a specificity of 0.60 and a negative predictive value of 0.94 (95% CI 0.89–0.98). Kaplan–Meier analysis confirmed that patients with an endoglin decrease greater than 0.588 ng/ml in the first 48 hrs had a significantly higher probability of cardiovascular death during follow-up than patients with lower values (P= 0.009) (Fig. 2).


Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction.

Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A, Martín-Moreiras J, Pericacho M, Sánchez PL, Ramirez V, Sánchez-Ledesma M, Martín-Herrero F, Jiménez-Candil J, Maree AO, Sánchez-Rodríguez A, Martín-Luengo C, López-Novoa JM - J. Cell. Mol. Med. (2008)

Overall survival in AMI patients stratified by early decrease in endoglin. Kaplan–Meier plot representing cumulative overall survival in patients with endoglin decrease (calculated as serum endoglin levels on admission minus serum endoglin levels 48 hrs later) above or below 0.588 ng/ml (value with the best sensitivity and specificity in the ROC analysis). (Log-rank test P= 0.009)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4401139&req=5

fig02: Overall survival in AMI patients stratified by early decrease in endoglin. Kaplan–Meier plot representing cumulative overall survival in patients with endoglin decrease (calculated as serum endoglin levels on admission minus serum endoglin levels 48 hrs later) above or below 0.588 ng/ml (value with the best sensitivity and specificity in the ROC analysis). (Log-rank test P= 0.009)
Mentions: The ROCAUC relating decrease in serum endoglin over the first 48 hrs to overall mortality was 0.65 (95% CI 0.55–0.81; P= 0.007). The highest likelihood ratio corresponded to an endoglin decrease of 0.588 ng/ml (positive likelihood ratio 1.73, negative likelihood ratio 0.49). This value had a sensitivity of 0.72, a specificity of 0.60 and a negative predictive value of 0.94 (95% CI 0.89–0.98). Kaplan–Meier analysis confirmed that patients with an endoglin decrease greater than 0.588 ng/ml in the first 48 hrs had a significantly higher probability of cardiovascular death during follow-up than patients with lower values (P= 0.009) (Fig. 2).

Bottom Line: Endoglin levels in AMI patients on admission were significantly lower than in healthy controls (4.25 +/- 0.99 ng/ml versus 4.59 +/- 0.87 ng/ml; P= 0.013), and decreased further in the first 48 hours (3.65 +/- 0.76 ng/ml, P < 0.001).Upon follow-up (median 319 days), patients who died had a significantly greater decrease in serum endoglin level over the first 48 hrs than those who survived (1.03 +/- 0.91 versus 0.54 +/- 0.55 ng/ml; P= 0.025).In conclusion, early changes in serum endoglin may predict mortality after AMI.

View Article: PubMed Central - PubMed

Affiliation: Cardiology Division, University Hospital of Salamanca, Salamanca, Spain.

ABSTRACT
Endoglin is a proliferation-associated and hypoxia-inducible protein expressed in endothelial cells. The levels of soluble circulating endoglin and their prognostic significance in patients with acute myocardial infarction (AMI) are not known. In this observational prospective study serum endoglin levels were measured by ELISA in 183 AMI patients upon admission to hospital and 48 hrs later and in 72 healthy controls. Endoglin levels in AMI patients on admission were significantly lower than in healthy controls (4.25 +/- 0.99 ng/ml versus 4.59 +/- 0.87 ng/ml; P= 0.013), and decreased further in the first 48 hours (3.65 +/- 0.76 ng/ml, P < 0.001). Upon follow-up (median 319 days), patients who died had a significantly greater decrease in serum endoglin level over the first 48 hrs than those who survived (1.03 +/- 0.91 versus 0.54 +/- 0.55 ng/ml; P= 0.025). Endoglin decrease was an independent predictor of short-term (30 days) (hazard ratio 2.33;95% CI = 1.27-4.23; P= 0.006) cardiovascular mortality, and also predicts overall cardiovascular mortality during the follow-up (median 319 days) in AMI patients (hazard ratio 2.13;95% CI = 1.20-3.78; P= 0.01). In conclusion, early changes in serum endoglin may predict mortality after AMI.

Show MeSH
Related in: MedlinePlus